Oncology · Tyrosine Kinase InhibitorRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for Danziten (Nilotinib Tartrate)

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 12:33:10 AM

Assessment confidence: 55% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for Danziten is a significant regulatory milestone that could strengthen AZURITY's competitive position in the oncology sector. Portfolio teams must assess the implications for market dynamics and prepare for potential competitive responses from other therapies in the same class. Regulatory context from FDA (FDA AP — DANZITEN (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should evaluate the potential market impact and prepare for competitive responses from other tyrosine kinase inhibitors. The strongest clinical anchor is The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Tyrosine Kinase Inhibitor, 8 regulatory and 4 competitive items passed relevance filtering for AZURITY.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Supplemental Application for KEYTRUDA QLEX (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from FDA Approves Supplement for KEYTRUDA (pembrolizumab) by Merck. This acceptance may enhance AZURITY's position in the oncology market, particularly in therapies targeting specific cancer types.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DANZITEN (SUPPL) (FDA). Entity match (azurity). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and labeling decisions will be critical to market entry.

Key Risks

Elevated medium regulatory exposure for AZURITY could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, Danziten could capture market share in a competitive oncology landscape, impacting revenue streams for both AZURITY and its competitors.
Oncology · PD-1 Inhibitor · Regulatory Approval · This acceptance may enhance Merck's competitive positioning in the oncology market, particularly in combination therapies.
Upside for AZURITY may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Upside for AZURITY may improve if Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for FDA review outcomes and any subsequent market entry strategies from AZURITY.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DANZITEN (SUPPL)
FDAhigh relevance
Entity match (azurity)
FDA document
View source
FDA AP — DANZITEN (SUPPL)
FDAhigh relevance
Entity match (azurity)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND ACETAMINOPHEN (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Oral Nutritional Supplement in Adults With or at Risk of Malnutrition
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Supplemental Application for KEYTRUDA QLEX
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Approves Supplement for KEYTRUDA (pembrolizumab) by Merck
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy)
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AZURITY
Danziten

Commercial impact

medium

If approved, Danziten could capture market share in a competitive oncology landscape, impacting revenue streams for both AZURITY and its competitors.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and labeling decisions will be critical to market entry.

What to watch

Monitor the timeline for FDA review outcomes and any subsequent market entry strategies from AZURITY.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.